Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chinese Patent Office
Colorcon
QuintilesIMS
Novartis
Julphar
McKesson
Daiichi Sankyo
Fuji
Express Scripts

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,686,026

« Back to Dashboard

Summary for Patent: 8,686,026
Title:Solid compositions
Abstract: The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
Inventor(s): Liepold; Bernd (Dossenheim, DE), Jung; Tina (Mannheim, DE), Holig; Peter (Waechtersbach, DE), Schroeder; Rudolf (Worms-Pfeddersheim, DE), Sever; Nancy E. (Arlington Heights, IL), Lafountaine; Justin S. (Chicago, IL), Sinclair; Brent D. (Grayslake, IL), Gao; Yi (Vernon Hills, IL), Wu; Jianwei (Libertyville, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:13/156,783
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation;

Drugs Protected by US Patent 8,686,026

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,686,026

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,006,387 Anti-viral compounds ➤ Subscribe
8,691,938 Anti-viral compounds ➤ Subscribe
9,586,978 Anti-viral compounds ➤ Subscribe
8,716,454 Solid compositions ➤ Subscribe
9,023,878 2-iminobiotin formulations and uses thereof ➤ Subscribe
8,937,150 Anti-viral compounds ➤ Subscribe
8,921,514 Anti-viral compounds ➤ Subscribe
9,676,797 Anti-viral compounds ➤ Subscribe
9,394,279 Anti-viral compounds ➤ Subscribe
9,616,135 2-iminobiotin formulations and uses thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,686,026

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 103819537 ➤ Subscribe
China 104193729 ➤ Subscribe
China 106986861 ➤ Subscribe
Colombia 6440538 ➤ Subscribe
Colombia 6660490 ➤ Subscribe
Colombia 6761348 ➤ Subscribe
Costa Rica 20120650 ➤ Subscribe
Costa Rica 20130170 ➤ Subscribe
Costa Rica 20140021 ➤ Subscribe
Cyprus 1114356 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Boehringer Ingelheim
Cipla
Johnson and Johnson
Merck
AstraZeneca
Queensland Health
Chinese Patent Office
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot